All funding news

Biotech funding news

15 recent Biotech rounds across our tracked sources.

C
🇨🇳Changyu PharmaPharmaceuticals

Changyu Pharma develops pharmaceutical products for the Chinese market.

$35MSeries D
Investor undisclosed
A $35M Series D for a China-focused pharma company in mid-2026 suggests domestic biotech is still attracting late-stage capital despite macro headwinds—but the undisclosed investor list is a yellow flag that this might be government-backed or a down round. If you're building biotech infrastructure (manufacturing, regulatory, supply chain), watch whether Changyu's next moves are geographic expansion or pure domestic consolidation; that'll tell you if Chinese pharma is ready to compete globally or just optimizing for domestic margin.
昌
🇨🇳

昌郁医药

Pharmaceuticals

昌郁医药 develops XG005, a novel pain treatment drug candidate advancing through clinical trials.

$35MSeries D
倚
倚锋资本
高嘉R
A $35M Series D for a pain drug in late-stage trials signals China's biotech investors are still backing clinical-stage assets despite global funding headwinds—but the bar is clearly higher (this is a smaller round than typical for this stage in 2024-25). If you're building in adjacent therapeutic areas or med-tech, watch whether XG005 clears Phase 3: Chinese pharma VCs are rotating capital toward companies with near-term regulatory wins, not just promising preclinics.
C
CORE BiomedicineBiotech

CORE Biomedicine develops biotech solutions for disease treatment and research applications.

$21MSeries A
Investor undisclosed
A $21M Series A for a biotech company in 2026 suggests the market is still funding platform plays in drug discovery/research tools, but the relatively modest check size hints investors are being selective—likely betting on CORE's specific technical moat rather than category tailwinds. If you're building in adjacent biotech infrastructure (lab automation, data platforms, regulatory software), this signals that generalist capital is still available, but you'll need a defensible technical angle, not just a problem statement.
T
🇸🇬Tikva AllocellCell Therapy

Tikva Allocell develops off-the-shelf allogeneic cell therapies targeting B7-H3+ solid tumors using engineered EBV-specific T cells.

$8MSeries A
K
Kantharos Capital
An $8M Series A for an allogeneic cell therapy in Singapore signals that off-the-shelf CAR-T is finally moving past the hype—this company is betting on EBV-specific T cells as a manufacturing shortcut to avoid the personalization bottleneck that's killed other programs. If you're building in adjacent cell therapy or immunotherapy, watch whether they can actually scale manufacturing; if they crack it, the playbook shifts from patient-specific to platform-based, which changes unit economics entirely.
N
N-Zyme BiomedicalBiotech

N-Zyme Biomedical develops enzyme-based biomedical solutions for therapeutic applications.

$4.6MSeries A
Investor undisclosed
A $4.6M Series A for an enzyme-therapy company signals biotech investors are still backing platform plays with narrow initial indications—this isn't a hot category moment, but rather patient capital betting on technical moats. They're likely funding manufacturing scale-up and IND-enabling studies, which means 18-24 months to clinical data. If you're in synthetic biology or protein engineering, watch whether N-Zyme's go-to-market strategy (licensing vs. direct development) becomes the template for other enzyme platforms.
果
🇨🇳

果核

Dental Tech

果核 builds intelligent orthodontic equipment for dental clinics using digital processing and manufacturing technology.

UndisclosedPre-A
Investor undisclosed
C
🇨🇳Changzhou HenghéMedical Devices

Changzhou Henghé develops surgical smoke evacuation and abdominal pressure management devices for precision surgery.

UndisclosedAngel
Investor undisclosed
D
🇨🇳Drug FarmDrug Discovery

Drug Farm accelerates pharmaceutical development through advanced drug discovery platforms for global biotech and pharma companies.

$55MSeries D
Investor undisclosed
A $55M Series D for a Chinese drug discovery platform signals that computational biotech is maturing past hype—this isn't seed-stage AI-for-drugs anymore, it's capital flowing to companies with actual pharma customer traction. If you're building B2B tools for regulated industries (biotech, medtech, materials), this validates that enterprises will pay for platforms that compress timelines, even if adoption cycles are long.
纽
🇨🇳

纽邦生物

Nutritional Supplements

纽邦生物 supplies dietary supplement raw materials to 600+ brands across China.

$28MSeries C+
Investor undisclosed
A $28M Series C+ for a supplement ingredient supplier signals China's nutraceutical market is consolidating around reliable, scaled manufacturers—this isn't about innovation hype, it's about supply chain defensibility. If you're building in adjacent health categories (functional foods, beauty-from-within, etc.), this shows there's real capital for B2B players who can lock in 600+ brand relationships and handle regulatory complexity. The round size suggests they're likely investing in vertical integration or geographic expansion rather than R&D, which means the moat is operational, not scientific.
A
Allotera TherapeuticsTherapeutics

Allotera Therapeutics develops allogeneic cell therapies for treating serious diseases.

$35M
Investor undisclosed
A $35M Series A for allogeneic cell therapy signals that off-the-shelf cell manufacturing is finally hitting the risk/reward sweet spot for investors—manufacturing scale and immune tolerance are becoming solvable, not theoretical. At this stage and size, Allotera is likely burning cash on GMP manufacturing, clinical trial setup, and IP moats around their allogeneic platform. If you're building in adjacent biotech (gene therapy, regenerative medicine, or even synthetic biology), watch whether they can actually solve the cost-per-dose problem that's killed previous allogeneic plays—that's the real gate.
B
🇨🇳BrainCoBrain-Computer Interface

BrainCo develops brain-computer interface technology that decodes neural signals for medical and commercial applications.

$2.8BPre-IPO
Investor undisclosed
A $2.8B pre-IPO round for a Chinese BCI company signals that neural decoding has moved from research curiosity to capital-scale commercialization—likely driven by regulatory clarity in China and real clinical/consumer traction. At this stage and size, they're probably scaling manufacturing, building out clinical evidence for specific indications (motor control, communication), and preparing for public markets. If you're in adjacent neurotech, assistive devices, or even consumer health hardware, watch their go-to-market playbook closely—this validates that the regulatory and reimbursement path exists, even if it's China-first.
德
🇨🇳

德睿智药

Pharmaceutical

德睿智药 develops AI-designed weight loss pharmaceuticals with Phase 3 clinical candidates.

$52MSeries B
Investor undisclosed
A $52M Series B for an AI-designed weight loss drug hitting Phase 3 signals China's biotech is moving past me-too generics into genuine drug discovery—and that obesity pharma is hot enough to fund even in a crowded space. If you're building biotech tooling or clinical-stage anything, watch whether Chinese VCs start demanding AI-designed candidates as table stakes; this round suggests they might.
华
🇨🇳

华源智因

AI Drug Discovery

华源智因 uses AI to model human cells and predict drug efficacy for pharmaceutical development.

UndisclosedSeed
Investor undisclosed
B
Beeline MedicinesDrug Discovery

Beeline Medicines uses AI to discover and develop novel drugs faster and more efficiently than traditional methods.

$126.3MSeries A Extension
Investor undisclosed
A $126M Series A extension signals that AI drug discovery has moved past the hype phase—investors are now betting on execution and clinical validation, not just the promise of faster screening. Beeline likely uses this to push candidates through preclinical/early clinical stages and prove the AI model actually reduces time-to-IND. If you're building in adjacent biotech infrastructure (lab automation, data platforms, regulatory tech), this validates that deep-pocketed founders will pay for tools that compress the discovery bottleneck.
Biobot Surgical logo
🇸🇬Biobot SurgicalMedical Robotics

Biobot Surgical builds robotic-assisted platforms for precise prostate biopsies and ablations using MRI-ultrasound fusion guidance.

$15.6MSeries B
C
ClavystBio
Z
A $15.6M Series B for a precision robotics play in urology signals that MRI-guided interventions are moving from research into reimbursable procedures—this is about de-risking the clinical pathway, not just building cooler hardware. If you're in adjacent image-guided surgery spaces (cardiac, orthopedic), watch whether Biobot's fusion approach becomes a standard-of-care requirement that forces your own roadmap.